CRISPR-Cas Technology Turns Chlamydomonas reinhardtii into a Flagship for Algal Biotechnology
Marine Drugs · 2025
DOI: 10.3390/md24010001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Marine Drugs, 2025. Verfasst von Amina Antonacci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monteroto…. Hauptthemen laut MEDLINE: Chlamydomonas reinhardtii, Biotechnology, CRISPR-Cas Systems, Microalgae. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN2022 Projects NANOgrab and BIODUST.
Abstract (Originalsprache)
Microalgae represent some of the most promising eukaryotic platforms in biotechnology due to their rapid growth, simple cultivation requirements, reliance on sunlight as a primary energy source, and ability to synthesize high-value bioactive compounds. These characteristics have made microalgae attractive candidates in various fields, including biofuel production, carbon capture, and pharmaceutical development. However, several technical limitations have limited their large-scale use as sustainable biofactories. A paradigm shift is currently occurring thanks to the genetic manipulation of microalgae, driven by CRISPR-Cas technology. Significant progress has been made in the model species Chlamydomonas reinhardtii, particularly in the targeted and efficient insertion of foreign DNA. Despite this progress, key challenges remain, and further optimization of CRISPR-Cas methodologies is needed to fully unleash the genetic potential of this organism. This review provides an overview of the convergence of CRISPR-Cas technologies in microalgae research, highlighting their impact on genetic studies, metabolic engineering, and industrial applications. It summarizes recent advances in microalgal genome editing through CRISPR systems, outlines current technical challenges, and highlights future directions for improving the implementation of this innovative technology in microalgal biotechnology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.
- Department of Biology, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cinthia 4, 80126 Naples, Italy.
ORCID-Profile: Amina Antonacci, Annalisa Masi, Vincenzo Vedi, Federica Musella, Gabriella Fiorentino, Viviana Scognamiglio
Förderung
- PRIN2022 Projects NANOgrab and BIODUST
Zitieren
APA
Antonacci, A., Masi, A., Vedi, V., Colella, S., Musella, F., Fiorentino, G., & Scognamiglio, V. (2025). CRISPR-Cas Technology Turns Chlamydomonas reinhardtii into a Flagship for Algal Biotechnology. Marine Drugs. https://doi.org/10.3390/md24010001
Vancouver
Antonacci A, Masi A, Vedi V, Colella S, Musella F, Fiorentino G, et al. CRISPR-Cas Technology Turns Chlamydomonas reinhardtii into a Flagship for Algal Biotechnology. Marine Drugs. 2025. doi:10.3390/md24010001
BibTeX
@article{Antonacci2025,
author = {Antonacci, Amina and Masi, Annalisa and Vedi, Vincenzo and Colella, Sara and Musella, Federica and Fiorentino, Gabriella and Scognamiglio, Viviana},
title = {CRISPR-Cas Technology Turns Chlamydomonas reinhardtii into a Flagship for Algal Biotechnology},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md24010001}
}
EUVIMED